Fig. 1

In vitro treatment effects of gemcitabine and IFN-β. a Dose response curves of gemcitabine and IFN-β on total DNA amount, as a measure of cell number, in ● BxPC-3, ■ CFPAC-1, and ▲ Panc-1 after 7 days of treatment. b Upper panel represents baseline mRNA expression of IFIT1, OAS1A, and Mx1 in BxPC-3 (left panel), CFPAC-1 (middle panel), and Panc-1 (right panel); Lower panel represent relative mRNA expression in untreated control cells and after 4 (white bar), 12 (light grey bar), 24 (dark grey bar), or 72 h (black bar) pre-treatment with IFN-β. c Experimental design for in vitro experiments. Cell were pre-treated with IFN-β for 4, 12, 24 or 72 h, followed by 72 h gemcitabine monotherapy. d EC₅₀ values of gemcitabine on cell growth in non-IFN-β pre-treated cells vs IFN-β pre-treated cells. EC₅₀ values are presented in nanogram per milliliter (ng/ml, 95% CI). EC₅₀ values depicted in bold represent the strongest decrease. Used concentrations IFN-β: 100 IU/ml for BxPC-3 and CFPAC-1, and 1000 IU/ml for Panc-1. Values represent mean ± SEM of at least two independent experiments in quadruplicate and are shown as the percentage of control. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control